125 related articles for article (PubMed ID: 30924955)
21. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
[TBL] [Abstract][Full Text] [Related]
22. Transport characteristics of tryptanthrin and its inhibitory effect on P-gp and MRP2 in Caco-2 cells.
Zhu X; Zhang X; Ma G; Yan J; Wang H; Yang Q
J Pharm Pharm Sci; 2011; 14(3):325-35. PubMed ID: 21824448
[TBL] [Abstract][Full Text] [Related]
23. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement.
Varma MV; Ashokraj Y; Dey CS; Panchagnula R
Pharmacol Res; 2003 Oct; 48(4):347-59. PubMed ID: 12902205
[TBL] [Abstract][Full Text] [Related]
24. In vitro to in vivo evidence of the inhibitor characteristics of Schisandra lignans toward P-glycoprotein.
Liang Y; Zhou Y; Zhang J; Liu Y; Guan T; Wang Y; Xing L; Rao T; Zhou L; Hao K; Xie L; Wang GJ
Phytomedicine; 2013 Aug; 20(11):1030-8. PubMed ID: 23731657
[TBL] [Abstract][Full Text] [Related]
25. Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.
Neuhoff S; Yeo KR; Barter Z; Jamei M; Turner DB; Rostami-Hodjegan A
J Pharm Sci; 2013 Sep; 102(9):3161-73. PubMed ID: 23686764
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of P-Glycoprotein Inhibitory Potential Using a Rhodamine 123 Accumulation Assay.
Jouan E; Le Vée M; Mayati A; Denizot C; Parmentier Y; Fardel O
Pharmaceutics; 2016 Apr; 8(2):. PubMed ID: 27077878
[TBL] [Abstract][Full Text] [Related]
27. Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information.
Umeyama Y; Fujioka Y; Okuda T
Xenobiotica; 2014 Dec; 44(12):1135-44. PubMed ID: 24937160
[TBL] [Abstract][Full Text] [Related]
28. Ex vivo and in vivo investigations of the effects of extracts of Vernonia amygdalina, Carica papaya and Tapinanthus sessilifolius on digoxin transport and pharmacokinetics: assessing the significance on rat intestinal P-glycoprotein efflux.
Oga EF; Sekine S; Horie T
Drug Metab Pharmacokinet; 2013; 28(4):314-20. PubMed ID: 23291634
[TBL] [Abstract][Full Text] [Related]
29. Effects of Kampo medicines on P-glycoprotein.
Satoh T; Watanabe Y; Ikarashi N; Ito K; Sugiyama K
Biol Pharm Bull; 2009 Dec; 32(12):2018-21. PubMed ID: 19952421
[TBL] [Abstract][Full Text] [Related]
30. Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P-glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers.
Wang X; Zhang ZY; Arora S; Hughes L; Wang J; Powers D; Christensen J; Lu S; Kansra V
J Clin Pharmacol; 2018 Feb; 58(2):202-211. PubMed ID: 28906558
[TBL] [Abstract][Full Text] [Related]
31. Tetrandrine potentiates the hypoglycemic efficacy of berberine by inhibiting P-glycoprotein function.
Shan YQ; Zhu YP; Pang J; Wang YX; Song DQ; Kong WJ; Jiang JD
Biol Pharm Bull; 2013; 36(10):1562-9. PubMed ID: 23924821
[TBL] [Abstract][Full Text] [Related]
32. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
Kim RB; Wandel C; Leake B; Cvetkovic M; Fromm MF; Dempsey PJ; Roden MM; Belas F; Chaudhary AK; Roden DM; Wood AJ; Wilkinson GR
Pharm Res; 1999 Mar; 16(3):408-14. PubMed ID: 10213372
[TBL] [Abstract][Full Text] [Related]
33. In vitro and in silico evaluation of P-glycoprotein inhibition through
Hosseini Balef SS; Piramoon M; Hosseinimehr SJ; Irannejad H
Chem Biol Drug Des; 2019 Mar; 93(3):283-289. PubMed ID: 30270513
[TBL] [Abstract][Full Text] [Related]
34. Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates.
Damont A; Goutal S; Auvity S; Valette H; Kuhnast B; Saba W; Tournier N
Eur J Pharm Sci; 2016 Aug; 91():98-104. PubMed ID: 27283486
[TBL] [Abstract][Full Text] [Related]
35. PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.
Hanke N; Frechen S; Moj D; Britz H; Eissing T; Wendl T; Lehr T
CPT Pharmacometrics Syst Pharmacol; 2018 Oct; 7(10):647-659. PubMed ID: 30091221
[TBL] [Abstract][Full Text] [Related]
36. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin.
Choi JS; Piao YJ; Kang KW
Arch Pharm Res; 2011 Apr; 34(4):607-13. PubMed ID: 21544726
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory effects of furanocoumarin derivatives in Kampo extract medicines on P-glycoprotein at the blood-brain barrier.
Iwanaga K; Yoneda S; Hamahata Y; Miyazaki M; Shibano M; Taniguchi M; Baba K; Kakemi M
Biol Pharm Bull; 2011; 34(8):1246-51. PubMed ID: 21804213
[TBL] [Abstract][Full Text] [Related]
38. The inhibitory effects of mitragynine on P-glycoprotein in vitro.
Rusli N; Amanah A; Kaur G; Adenan MI; Sulaiman SF; Wahab HA; Tan ML
Naunyn Schmiedebergs Arch Pharmacol; 2019 Apr; 392(4):481-496. PubMed ID: 30604191
[TBL] [Abstract][Full Text] [Related]
39. Use of a Caco-2 permeability assay to evaluate the effects of several Kampo medicines on the drug transporter P-glycoprotein.
Matsumoto T; Kaifuchi N; Mizuhara Y; Warabi E; Watanabe J
J Nat Med; 2018 Sep; 72(4):897-904. PubMed ID: 29797179
[TBL] [Abstract][Full Text] [Related]
40. Furanocoumarin derivatives in Kampo extract medicines inhibit cytochrome P450 3A4 and P-glycoprotein.
Iwanaga K; Hayashi M; Hamahata Y; Miyazaki M; Shibano M; Taniguchi M; Baba K; Kakemi M
Drug Metab Dispos; 2010 Aug; 38(8):1286-94. PubMed ID: 20463004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
